Download or read book BRAF Targets in Melanoma written by Ryan J. Sullivan and published by Springer. This book was released on 2014-11-24 with total page 206 pages. Available in PDF, EPUB and Kindle. Book excerpt: ​This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that this drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.

Download or read book Sunlight Vitamin D and Skin Cancer written by Jörg Reichrath and published by Springer Nature. This book was released on 2020-09-11 with total page 428 pages. Available in PDF, EPUB and Kindle. Book excerpt: The third edition is a comprehensive and updated overview of positive and negative effects of UV-exposure, with a focus on Vitamin D and skin cancer. Researchers, oncologists,and students will be provided with the most significant and timely information related to topics such as the epidemiology of skin cancer, the immune system and skin cancer, ultraviolet damage, DNA repair and Vitamin D in Nonmelanoma skin cancer and malignant melanoma. There have been a number of new, scientific findings in this fast moving field that necessitated a thoroughly updated and revised edition including new Vitamin D metabolites and skin cancer, new findings on the beneficial effects of UV and solar UV and skin cancer, adverse effects of sun protection and sunscreens, sun exposure and mortality, and more. The book will summarize essential, up-to-date information for every clinician or scientist interested in how to balance the positive and negative effects of UV‐exposure to minimize the risks of developing vitamin D deficiency and skin cancer.

Download or read book Melanoma written by William H. Sharfman, MD and published by Demos Medical Publishing. This book was released on 2012-12-17 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt: This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of melanoma treatment. Due to recent drug approvals and increasing ability to offer combined agents, there are many more treatment options available to melanoma patients than even a few years ago. Especially significant are the recent FDA approval of the immunotherapeutic agent ipilimumab for metastatic melanoma, and new agents targeting the BRAF gene in malignant melanoma (these two developments cited among the top 5 most significant advances in oncology for 2011). There is also coverage of the most recent data pertaining to surgical management, staging and prevention, and melanoma in children. The authorship of the articles is outstanding and represents national and global authorities on the topics reviewed.

Download or read book BRAF Mutation as a Target for Treatment of Melanoma written by Andrea Aquilato and published by . This book was released on 2012 with total page 61 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Cutaneous Melanoma written by and published by . This book was released on with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Melanoma written by Guy Huynh Thien Duc and published by BoD – Books on Demand. This book was released on 2013-01-30 with total page 734 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Book "Melanoma - From Early Detection To Treatment" is aiming to present data and knowledge from most experienced experts in the field. The book covers main topics from the fundamental aspects to multiple approaches in the disease treatment as well as related features. It offers a global view concerning one of the most frequent types of cancer to which a substantial high proportion of people worldwide is confronted at some time point in life.

Download or read book Molecular Surgical Pathology written by Liang Cheng and published by Springer Nature. This book was released on 2023-10-31 with total page 725 pages. Available in PDF, EPUB and Kindle. Book excerpt: Since the first edition of this book in 2012, the field of molecular pathology has expanded exponentially. The advent of complete cancer genome sequencing, new diagnostic molecular tests, and biomarkers for targeted therapy and immunotherapy have demonstrated the importance of molecular tools both in patient care and in the practice of pathology. Furthermore, the development of many new molecular technologies has revolutionized the practice of modern pathology. The rapid growth of this field has led to an expansion of knowledge of molecular processes and many more clinical applications in our daily practice of surgical pathology. Thus, this updated second edition of Molecular Surgical Pathology aims to serve as the best available “quick reference” for pathologists, oncologists, geneticists, primary care physicians, and other medical professionals with an interest in this specialty. Molecular Surgical Pathology 2nd Edition focuses on the practical utility of molecular techniques and on molecular biomarkers for the practicing surgical pathologist. The emphasis is on the impact of molecular pathology for tumor classification, diagnosis and differential diagnosis, as well as its implications for patient management and personalized care. This concise overview of molecular surgical pathology and molecular classification of tumors of different organ sites will help not only practicing physicians, but also those in training, including residents and fellows in various disciplines.

Download or read book Identifying and Targeting Mechanisms of Resistance to BRAF Inhibitors written by Mahamat Babagana and published by Createspace Independent Publishing Platform. This book was released on 2017-09-04 with total page 160 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cutaneous melanoma is the most fatal type of skin cancer. The steady increase in incidence and static mortality rates have intensified the need to improve melanoma therapeutics. Constitutive activation of the growth signaling mitogen activated protein kinase (MAPK) pathway, frequently due to mutations in the proto-oncoprotein BRAF (BRAFV600E), has been found to provide the perpetual mitogenic signal needed for continued proliferation in many cancers, including melanoma. Although direct targeting of BRAF signaling has had some benefit for patients in the treatment of metastatic melanoma, it does not suffice in providing a lasting cure among the majority of responders due to acquired resistance. Additionally, a large subset of patients, who contain mutant BRAF, do not respond to BRAF inhibition due to intrinsic resistance. Because of the high occurrence of activating BRAF mutations in melanoma and other cancers and the limited efficacy of MAPK pathway targeting drugs due to acquired and intrinsic resistance, there is an immense need to identify additional strategies that can be used to safely increase the efficacy of MAPK pathway inhibitors. Here we demonstrate that the serine/threonine p21 activated kinase (PAK1) is a converging point used by several pathways to provide resistance to MAPK pathway inhibitors. Moreover, PAK1 inhibition can revert acquired and intrinsic resistance to MAPK pathway inhibitors. In addition, we show that polo-like kinase 3 (PLK3) can modulate MAPK pathway inhibitor efficacy in vitro and in vivo. Concurrently, there is a significant correlation of increased PLK3 expression in relapsed patient tumors and in many melanoma cell lines that are relatively resistant to MAPK pathway inhibitors. We have also identified that increased stimulation of the serine/threonine kinase, AKT, which itself has be shown to drive cancer progression and resistance to many types of therapy, including BRAF inhibitors, enhances cellular toxicity associated with exposure to increased temperatures. Our results identify patient subgroups who are at high risk for failure to current targeted therapeutics used for the treatment of BRAF mutated cancers. Additionally, we identify novel avenues which could be targeted to increase the efficacy of MAPK pathway inhibitors in melanoma and other BRAF mutated cancers. Our findings also support hyperthermia as a therapeutic approach which could be used to selectivity target a wide range of cancers cells with increased AKT signaling.

Download or read book Human Skin Cancers written by Miroslav Blumenberg and published by BoD – Books on Demand. This book was released on 2018-05-02 with total page 214 pages. Available in PDF, EPUB and Kindle. Book excerpt: Human skin cancers, the most common type of tumors, represent a significant health burden. The deadliest is unquestionably melanoma. Half of melanomas have an activating mutation in the BRAF gene, prompting development of novel drugs, vemurafenib and dabrafenib, specifically targeting mutated BRAF. Trametinib and cobimetinib, which block MEK, a BRAF effector protein, have been used in combination with BRAF inhibitors. A promising new melanoma treatment is immunotherapy, approach that boosts patient's own immune system to attack cancer. Pembrolizumab and nivolumab inhibit PD-1, whereas Ipilimumab targets CTLA-4, another immunity check point, to boost the immune response. Here we focus on pathways, mechanisms, targets and treatments of human skin cancers, with particular emphasis on the new developments in the research on melanomas.

Download or read book Melanoma written by Sanjiv S. Agarwala and published by CRC Press. This book was released on 2008-08-08 with total page 225 pages. Available in PDF, EPUB and Kindle. Book excerpt: Assembling, reviewing, and synthesizing state-of-the-art information on translational research and therapies of melanoma into one convenient source, Melanoma: Translational Research and Emerging Therapies provides clinicians and researchers the necessary context and perspective to intergrate and effectively deploy cutting-edge therapies into daily

Download or read book Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma written by Michael J. Murphy and published by Springer Science & Business Media. This book was released on 2011-12-02 with total page 328 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book describes both the technologies used in the discovery of melanoma biomarkers and the clinical application of these biomarkers for diagnosis and staging of disease, determination of prognosis, treatment planning, monitoring of response to therapy, identification of novel therapeutic targets and drug development. A broad range of biomarkers (DNA/chromosomal, mRNA, microRNA, mitochondrial DNA, epigenetic and protein) is outlined. As therapies for melanoma become increasingly more target specific, the identification, validation and use of biomarkers will invariably play a greater role in the management of patients with this disease. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma is an essential resource for oncologists, dermatologists, dermatopathologists, general pathologists with an interest in melanoma, and melanoma researchers.

Download or read book Genetics of Melanoma written by Carlos A. Torres-Cabala and published by Springer. This book was released on 2016-05-11 with total page 291 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book discusses the molecular, biological, pathological, and clinical aspects of melanoma, with special emphasis in the new concepts of melanoma genetics. A multidisciplinary group of experts in Genetics, Dermatology, Pathology, and Melanoma Medical Oncology contribute state-of-the-art knowledge in melanoma research and clinical management, not only exposing the current status of knowledge of the topics but also providing their personal experiences and ideas about the future and potential practical application of the genetic aspects of melanoma. During the last few years we have witnessed an impressive amount of discoveries in the field of melanoma genetics which have changed our approach in understanding the pathogenesis and treatment of this lethal disease. Genetics of Melanoma is a practical approach to melanoma genetic mechanisms and their application in the diagnosis and treatment of this malignancy. It is an essential source of updated information and a powerful tool for clinicians, pathologists, and basic scientists who wish to understand, apply, and investigate the multiple new aspects of melanoma genetics.

Download or read book Targeted Therapeutics in Melanoma written by Thomas F. Gajewski and published by Springer Science & Business Media. This book was released on 2011-12-15 with total page 377 pages. Available in PDF, EPUB and Kindle. Book excerpt: Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.

Download or read book Melanoma written by Mandi Murph and published by BoD – Books on Demand. This book was released on 2015-04-01 with total page 414 pages. Available in PDF, EPUB and Kindle. Book excerpt: Melanoma - Current Clinical Management and Future Therapeutics serves as an advanced course in melanoma or an addendum to further polish expertise. Sections of the book include a thorough introduction on epidemiology and disease, the current surgical management of melanoma and lymph node dissection, immunotherapy along with drug toxicities and emerging research topics, like RAGE and autotaxin, that have potential therapeutic applications. The chapters in this book explore the most common subtype of melanoma, cutaneous disease, as well as a rare form, acral lentiginous melanoma and even canine tumors. Experts from around the globe contributed chapters, most of which have visual illustrations to depict aspects of disease management and therapy, allowing readers to grasp the advanced concepts presented.

Download or read book Recent Advances in the Biology Therapy and Management of Melanoma written by Lester Davids and published by BoD – Books on Demand. This book was released on 2013-02-13 with total page 388 pages. Available in PDF, EPUB and Kindle. Book excerpt: The book Recent Advances in the Biology, Therapy and Management of Melanoma brings up-to-date information regarding a number of aspects which culminate in illuminating potential targets in the fight against melanoma. This book is intended to be a reference book for both the scientific and clinical communities and brings complicated subject matter together in an easy, readable way. Undoubtedly fundamental scientific understanding has to then be translated to the clinic in order for us to make significant strides in eradicating melanoma. It is hoped that scientists, clinicians, students and residents find this book useful in their studies on melanoma and that it not only expands their perspectives and views on the field, but challenges them to forge ahead towards discovering the ultimate cure.

Download or read book Research on Melanoma written by Mandi Murph and published by BoD – Books on Demand. This book was released on 2011-09-12 with total page 430 pages. Available in PDF, EPUB and Kindle. Book excerpt: The book Research on Melanoma: A Glimpse into Current Directions and Future Trends, is divided into sections to represent the most cutting-edge topics in melanoma from around the world. The emerging epigenetics of disease, novel therapeutics under development and the molecular signaling aberrations are explained in detail. Since there are a number of areas in which unknowns exist surrounding the complex development of melanoma and its response to therapy, this book illuminates and comprehensively discusses such aspects. It is relevant for teaching the novice researcher who wants to initiate projects in melanoma and the more senior researcher seeking to polish their existing knowledge in this area. Many chapters include visuals and illustrations designed to easily guide the reader through the ideas presented.

Download or read book Examining Mechanisms of RAF Inhibitor Resistance in Mutant BRAF Melanoma written by Kevin Joseph Basile and published by . This book was released on 2013 with total page 602 pages. Available in PDF, EPUB and Kindle. Book excerpt: The identification of BRAF V600E as a driving mutation in approximately 50% of melanoma and the subsequent development of therapies that specifically target mutant BRAF signaling has brought new hope to many patients that suffer with this disease. However, despite initial tumor regression, almost all patients treated with RAF inhibitors develop resistance. While these RAF inhibitors are initially capable of inhibiting ERK1/2 signaling in patients that respond to treatment, the temporal kinetics of ERK1/2 activity in relation to tumor regression and tumor regrowth remain poorly defined. Several mechanisms of acquired resistance to RAF inhibitors have been identified; however, many cases of tumor progression have not been explained. Additionally, mechanisms of intrinsic resistance to RAF inhibitors have not been extensively studied. Patients that progress while on RAF inhibitor treatment are left with no effective second-line therapeutic options and ultimately succumb to the disease. Here, we found that increased expression of the stemness factor, FOXD3, in response to inhibition of ERK1/2 signaling mediates intrinsic resistance to RAF inhibitor treatment by increasing expression of ERBB3. Depletion of FOXD3 expression or direct/indirect inhibition of ERBB3 signaling sensitized cells/tumors to RAF inhibitors. Additionally, we characterized the role of Noxa downregulation in response to RAF/MEK inhibition and demonstrated that restoration of Noxa expression increased the cell death response of mutant BRAF melanoma cells to RAF/MEK targeted therapies. Finally, we used a novel, cell-based ERK1/2 reporter system to fully characterize the relationship of ERK1/2 signaling in relation to RAF inhibitor-mediated tumor regression and subsequent tumor regrowth. We identified novel molecular changes associated with tumors that acquired resistance to RAF inhibitor treatment and demonstrated that next-generation "paradox breaker" RAF inhibitors show efficacy in treating cells that have developed resistance to first-generation RAF inhibitors. These findings thoroughly explore the stages and progression of RAF inhibitor resistance, characterize new mechanisms of RAF inhibitor resistance and identify new treatment options that would benefit both treatment-naive and resistant patients.